Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $20.38
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 22, 26 |
Daily · Wilder smoothing
| JP Morgan |
| maintain |
| Overweight |
| Overweight |
| Sep 17, 26 | Barclays | maintain | Overweight | Overweight |
| Aug 3, 26 | UBS | maintain | Buy | Buy |
| Jul 15, 26 | UBS | maintain | Buy | Buy |
| May 20, 26 | Barclays | maintain | Overweight | Overweight |
| Mar 2, 26 | Truist Securities | maintain | Buy | Buy |
| Oct 31, 25 | Piper Sandler | maintain | Overweight | Overweight |
| Sep 16, 25 | JP Morgan | maintain | Overweight | Overweight |
| Mar 3, 25 | Barclays | maintain | Overweight | Overweight |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 60.79 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 86.37 | Oscillator | Sell |
| Williams %R (14) | -12.15 | Oscillator | Sell |
| MACD (12, 26, 9) | 0.33 (Hist 0.00) | Oscillator | Strong Buy |
| Average Directional Index (14) | 18.53 (+DI 26.1 / -DI 20.5) | Trend | Neutral |
| EMA 20 | 19.69 | MA | Strong Buy |
| SMA 20 | 19.91 | MA | Buy |
| EMA 50 | 18.96 | MA | Strong Buy |
| SMA 50 | 18.81 | MA | Strong Buy |
| SMA 200 | 15.54 | MA | Strong Buy |
TTM vs. 5-year historical average (annual ratios)
| Metric | AMRX | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 41.0x | 17.5x · sector 20.7x | Elevated |
| Forward P/E (FY26E) | 19.8x | EPS est. 1.03 | Discount |
| Price / Book | 197.0x | -4.3x | Discount |
| Price / Sales | 2.1x | 0.6x | Elevated |
| EV / EBITDA | 14.1x | 8.9x | Elevated |
| Return on equity | -326.8% | — | Weak |
| Gross margin | 39.3% | 36.6% | In line |
| Debt / Equity | 84.54 | 18.84 | Levered |
| Piotroski / Altman Z | 7/9 | Z 2.48 | Grey zone |
Discounted cash flow model
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 17, 26 | Buchi J Kevin | director | G-Gift | 20,445 | — |
| Sep 11, 26 |
| Buchi J Kevin |
| director |
| M-Exempt |
| 20,445 @ $14.45 |
| $295.4K |
| Sep 11, 26 | Buchi J Kevin | director | M-Exempt | 20,445 @ $14.45 | $295.4K |
| Sep 1, 26 | Boyer Andrew S | officer: Executive Vice President | G-Gift | 80,000 | — |
| Aug 21, 26 | Boyer Andrew S | officer: Executive Vice President | G-Gift | 152,426 | — |
| Aug 13, 26 | Kiely John | director | S-Sale | 50,000 @ $17.64 | $882.0K |
| Aug 13, 26 | Kiely John | director | G-Gift | 10,000 | — |
| Aug 12, 26 | Shah Nikita | officer: Executive Vice President | S-Sale | 146,403 @ $17.51 | $2.56M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K/A | Oct 23, 2026 | 2026-10-23 16:05:33 | View |
| 4 | Sep 21, 2026 | 2026-09-21 16:33:26 | View |
| 4 | Sep 14, 2026 | 2026-09-14 16:10:38 | View |
| S-3ASR | Sep 3, 2026 | 2026-09-03 16:44:14 | View |
| 4 | Sep 2, 2026 | 2026-09-02 17:03:34 | View |
| 4 | Aug 25, 2026 | 2026-08-25 16:41:33 | View |
| 4 | Aug 14, 2026 | 2026-08-14 16:29:24 | View |
| 4 | Aug 13, 2026 | 2026-08-13 16:22:00 | View |
| 4 | Aug 13, 2026 | 2026-08-13 16:21:37 | View |
| 4 | Aug 13, 2026 | 2026-08-13 16:21:02 | View |
Proxy statement (DEF 14A) disclosures
Stock news · updated daily
Amneal Pharmaceuticals (NASDAQ: AMRX - Get Free Report) and Neurocrine Biosciences (NASDAQ: NBIX - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, institutional ownership and valuation. Analyst Ratings This is a breakdown of recent
BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.
BRIDGEWATER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report third quarter 2026 financial results on Tuesday, November 3, 2026, before market open. The Company will host an audio webcast at 8:30 a.m. ET.
On September 28, 2026, Amneal Pharmaceuticals Inc (AMRX) shares rose 3.7% to $20.50, reflecting strong price performance especially in the context of its 52-wee
- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production
Amneal (AMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
On September 15, 2026, Amneal Pharmaceuticals Inc (AMRX) shares fell 3.3% to $16.65. This decline comes amid a 52-week trading range of $9.49 to $19.26, indicat
COCO, DAR, CNC, EXC and AMRX offer a defensive appeal as consumer confidence hits a 7-month low amid inflation and labor market concerns.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 30, 2026 | 0.22 | 0.30 | Beat 34.8% | $796.2M |
| May 7, 2026 | 0.17 | 0.27 | Beat 58.8% | $722.5M |
| Feb 27, 2026 | 0.18 | 0.21 | Beat 16.7% | $814.3M |
| Oct 30, 2025 | 0.13 | 0.17 | Beat 30.8% | $784.5M |
| Aug 5, 2025 | 0.18 | 0.25 | Beat 38.9% | $724.5M |
| May 2, 2025 | 0.15 | 0.21 | Beat 40.0% | $695.4M |